Phase 3 Type 2 Diabetes Trial, RecruitingNCT07392190Sponsor: Eli Lilly and CompanyCondition: Type 2 Diabetes
Printed from Voxsanity (voxsanity.com.au) — NCT07392190 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.
AI generated eligibility summary.
Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source.
How we use AI
Who might be able to join this trial:
People who are currently taking a stable dose of incretin-based medication (a type of medication used for blood sugar or weight management) at the time of screening.
People with a body mass index (BMI) of 30 or higher, OR a BMI of 27 or higher along with at least one related health condition such as high blood pressure, abnormal cholesterol levels, obstructive sleep apnea, certain heart conditions, or type 2 diabetes.
People whose body weight has been stable (less than 5% change) leading up to the screening period.
Who may not be able to join:
People who have had, or are planning to have, surgery to treat obesity (note: liposuction, cryolipolysis, or tummy tuck procedures performed more than 1 year before screening may be acceptable — confirm with trial site).
People who have had, or are planning to have, an endoscopic or device-based procedure to treat obesity (prior device removal more than 6 months before screening may be acceptable — confirm with trial site).
People who have type 1 diabetes.
People who have taken certain blood sugar-lowering medications — specifically DPP-4 inhibitors, amylin analogs, or insulin — within the 90 days before screening.
People who have experienced a heart attack, stroke, a procedure to reopen blocked heart arteries, unstable chest pain, or a hospital stay due to heart failure within the 90 days before screening.
People who have been diagnosed with the most severe category of heart failure (Class IV under the New York Heart Association classification).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.
Contact this trial
Principal Investigator: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST), Eli Lilly and Company
Royal Brisbane and Women's Hospital, Brisbane,
+61736468111
Emeritus Research, Camberwell,
Barwon Health, Geelong,
Austin Health - Repatriation Hospital, Heidelberg West,
0394962160
AIM Research, Merewether,
+61 2 4963 2323
Southern Adelaide Diabetes & Endocrine Services, Oaklands Park,
0874258693
Royal North Shore Hospital, St Leonards,
Innovate Clinical Research, Waitara,
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Voxsanity
Clinical trials and treatments, explained plainly · voxsanity.com.au
Date:
To: My Doctor
Re: Clinical trial enquiry
I am writing to enquire about the following clinical trial which may be relevant to my care:
Trial: NCT07392190
Sponsor: Eli Lilly and Company
Phase: Phase 3
Status: Recruiting
Condition: Type 2 Diabetes
Trial contact: 317-615-4559
More information: https://clinicaltrials.gov/study/NCT07392190
Eligibility summary (AI generated)
Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.
Who might be able to join this trial:
People who are currently taking a stable dose of incretin-based medication (a type of medication used for blood sugar or weight management) at the time of screening.
People with a body mass index (BMI) of 30 or higher, OR a BMI of 27 or higher along with at least one related health condition such as high blood pressure, abnormal cholesterol levels, obstructive sleep apnea, certain heart conditions, or type 2 diabetes.
People whose body weight has been stable (less than 5% change) leading up to the screening period.
Who may not be able to join:
People who have had, or are planning to have, surgery to treat obesity (note: liposuction, cryolipolysis, or tummy tuck procedures performed more than 1 year before screening may be acceptable — confirm with trial site).
People who have had, or are planning to have, an endoscopic or device-based procedure to treat obesity (prior device removal more than 6 months before screening may be acceptable — confirm with trial site).
People who have type 1 diabetes.
People who have taken certain blood sugar-lowering medications — specifically DPP-4 inhibitors, amylin analogs, or insulin — within the 90 days before screening.
People who have experienced a heart attack, stroke, a procedure to reopen blocked heart arteries, unstable chest pain, or a hospital stay due to heart failure within the 90 days before screening.
People who have been diagnosed with the most severe category of heart failure (Class IV under the New York Heart Association classification).
Important: Always verify eligibility with the trial site directly before applying.
Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.
This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.
🇦🇺 Australia
🇧🇪 Belgium
🇧🇷 Brazil
🇨🇳 China
🇨🇿 Czechia
🇮🇱 Israel
🇯🇵 Japan
🇲🇽 Mexico
Puerto Rico
🇷🇴 Romania
🇪🇸 Spain
🇹🇼 Taiwan
🇺🇸 United States
10 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percent Change from Baseline in Body Weight
Can't join this trial?
Expanded access pathways
If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.
Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.